Skip to main content
Top
Published in: American Journal of Clinical Dermatology 9/2002

01-12-2002 | Review Article

Adverse Cutaneous Reactions to Antipsychotics

Authors: Dr Julia K. Warnock, David W. Morris

Published in: American Journal of Clinical Dermatology | Issue 9/2002

Login to get access

Abstract

Antipsychotic agents are known to cause adverse cutaneous reactions in approximately 5% of the individuals for whom they are prescribed. The majority of adverse cutaneous events are benign and easily treated, and do not place the patient at a serious health risk. However, these adverse events may impact on compliance so discussing strategies with the patient to avoid potential adverse cutaneous effects will improve compliance. The most frequently reported cutaneous adverse effects of antipsychotic medications include: exanthematous eruptions, skin pigmentation changes, photosensitivity, urticaria and pruritus. Only a small percentage of adverse cutaneous reactions are life threatening. The most important step in minimizing morbidity is prompt recognition of severe drug reactions with withdrawal of the causative medication. If a skin eruption occurs in an outpatient setting, it is generally advisable to discontinue the drug and to consider switching to another class of agent. If the reaction is mild, and the therapeutic benefits far exceed the risks of the symptomatic treatment, then the antipsychotic agent may be continued.
Footnotes
1
Use of tradenames is for product identification purposes only and does not imply endorsement.
 
Literature
1.
go back to reference Srebrnik A., Hes J.P., Brenner S. Adverse cutaneous reactions to psychotropic drugs. Acta Derm Venereol 1991; 158: 3–12 Srebrnik A., Hes J.P., Brenner S. Adverse cutaneous reactions to psychotropic drugs. Acta Derm Venereol 1991; 158: 3–12
2.
go back to reference Stahl S.M. Essential psychopharmacology: neuroscientific basis and practical application. 2nd ed. Cambridge: Cambridge University Press, 2000 Stahl S.M. Essential psychopharmacology: neuroscientific basis and practical application. 2nd ed. Cambridge: Cambridge University Press, 2000
3.
go back to reference Medical Economics. Physician’s desk reference. 55th ed. Montvale (NJ): Medical Economics, 2001 Medical Economics. Physician’s desk reference. 55th ed. Montvale (NJ): Medical Economics, 2001
4.
go back to reference Medical Economics. Physician’s desk reference. 48th ed. Montvale (NJ): Medical Economics, 1994 Medical Economics. Physician’s desk reference. 48th ed. Montvale (NJ): Medical Economics, 1994
5.
go back to reference Garnis-Jones S. Dermatologic side effects of psychopharmacologic agents. Dermatol Clin 1996; 14 (3): 503–8PubMedCrossRef Garnis-Jones S. Dermatologic side effects of psychopharmacologic agents. Dermatol Clin 1996; 14 (3): 503–8PubMedCrossRef
6.
go back to reference Pavlidakey G.P., Hashimoto K., Heller G.L., et al. Chlorpromazine-induced lupus-like disease: case report and review of the literature. J Am Acad Dermatol 1985; 13 (1): 109–15PubMedCrossRef Pavlidakey G.P., Hashimoto K., Heller G.L., et al. Chlorpromazine-induced lupus-like disease: case report and review of the literature. J Am Acad Dermatol 1985; 13 (1): 109–15PubMedCrossRef
7.
go back to reference MacMorran W.S., Krahn L.E. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics 1997; 38 (5): 413–22PubMedCrossRef MacMorran W.S., Krahn L.E. Adverse cutaneous reactions to psychotropic drugs. Psychosomatics 1997; 38 (5): 413–22PubMedCrossRef
8.
go back to reference Gold M.S., Sweeney D.R. Perphenazine-induced systemic lupus erythematosus-like syndrome. J Nerv Ment Dis 1978; 166 (6): 442–5PubMedCrossRef Gold M.S., Sweeney D.R. Perphenazine-induced systemic lupus erythematosus-like syndrome. J Nerv Ment Dis 1978; 166 (6): 442–5PubMedCrossRef
9.
go back to reference McNevin S., MacKay M. Chlorprothixene-induced systemic lupus erythematosus. J Clin Psychopharmacol 1982; 2 (6): 411–2PubMedCrossRef McNevin S., MacKay M. Chlorprothixene-induced systemic lupus erythematosus. J Clin Psychopharmacol 1982; 2 (6): 411–2PubMedCrossRef
10.
go back to reference Dubois E.L., Tallman E., Wonka R.A.. Chlorpromazine-induced systemic lupus erythematosus: case report and review of the literature. JAMA 1972; 221 (6): 595–6PubMedCrossRef Dubois E.L., Tallman E., Wonka R.A.. Chlorpromazine-induced systemic lupus erythematosus: case report and review of the literature. JAMA 1972; 221 (6): 595–6PubMedCrossRef
11.
go back to reference Warnock J.K., Knesevich J.W. Adverse cutaneous reactions to antidepressants. Am J Psychiatry 1988; 145: 425–30PubMed Warnock J.K., Knesevich J.W. Adverse cutaneous reactions to antidepressants. Am J Psychiatry 1988; 145: 425–30PubMed
12.
go back to reference Scuderi S., Gift T.E. Thiothixene induced edema. Psychiatr Med 1986; 4 (3): 249–52PubMed Scuderi S., Gift T.E. Thiothixene induced edema. Psychiatr Med 1986; 4 (3): 249–52PubMed
13.
go back to reference Hamann G.L., Egan T.M., Wells B.G., et al. Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. J Clin Psychiatry 1990; 51 (12): 502–4PubMed Hamann G.L., Egan T.M., Wells B.G., et al. Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. J Clin Psychiatry 1990; 51 (12): 502–4PubMed
14.
15.
go back to reference Reilly G.D., Wood M.L. Prochlorperazine: an unusual cause of lip ulceration. Acta Derm Venereol 1984; 64 (3): 270–1PubMed Reilly G.D., Wood M.L. Prochlorperazine: an unusual cause of lip ulceration. Acta Derm Venereol 1984; 64 (3): 270–1PubMed
16.
go back to reference Matsuo I., Ozawa A., Niizuma K., et al. Lichenoid dermatitis due to chlorpromazine phototoxicity. Dermatologica 1979; 159 (1): 46–9PubMedCrossRef Matsuo I., Ozawa A., Niizuma K., et al. Lichenoid dermatitis due to chlorpromazine phototoxicity. Dermatologica 1979; 159 (1): 46–9PubMedCrossRef
17.
go back to reference Eberlein-Konig B., Bindl A., Przybilla B. Phototoxic properties of neuroleptic drugs. Dermatology 1997; 194 (2): 131–5PubMedCrossRef Eberlein-Konig B., Bindl A., Przybilla B. Phototoxic properties of neuroleptic drugs. Dermatology 1997; 194 (2): 131–5PubMedCrossRef
18.
go back to reference Harth Y., Rapoport M. Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Drug Saf 1996; 14 (4): 252–9PubMedCrossRef Harth Y., Rapoport M. Photosensitivity associated with antipsychotics, antidepressants and anxiolytics. Drug Saf 1996; 14 (4): 252–9PubMedCrossRef
19.
go back to reference Fitzpatrick T.B., Johnson R.A., Wolff K., et al. Color atlas and synopsis of clinical dermatology: common and serious diseases. 4th ed. New York: McGraw-Hill, 2001 Fitzpatrick T.B., Johnson R.A., Wolff K., et al. Color atlas and synopsis of clinical dermatology: common and serious diseases. 4th ed. New York: McGraw-Hill, 2001
20.
go back to reference Satanove A. Pigmentation due to phenothiazines in high and prolonged dosage. JAMA 1965; 191 (4): 263–8PubMedCrossRef Satanove A. Pigmentation due to phenothiazines in high and prolonged dosage. JAMA 1965; 191 (4): 263–8PubMedCrossRef
21.
go back to reference Robins A.H. Phenothiazine melanosis in schizophrenic patients. Psychopharmacologia 1972; 27 (4): 327–42PubMedCrossRef Robins A.H. Phenothiazine melanosis in schizophrenic patients. Psychopharmacologia 1972; 27 (4): 327–42PubMedCrossRef
22.
go back to reference Forrest F.M., Snow H.L., Erickson G., et al. Incidence of late ‘melanosis’ side effects in chronic mental patients after long term phenothiazine therapy. Proc West Pharmacol Soc 1966; 9: 18–20PubMed Forrest F.M., Snow H.L., Erickson G., et al. Incidence of late ‘melanosis’ side effects in chronic mental patients after long term phenothiazine therapy. Proc West Pharmacol Soc 1966; 9: 18–20PubMed
23.
go back to reference Gibbard B.A., Lehmann H.E. Therapy of phenothiazine-produced skin pigmentation: a preliminary report. Am J Psychiatry 1966; 123 (3): 351–2PubMed Gibbard B.A., Lehmann H.E. Therapy of phenothiazine-produced skin pigmentation: a preliminary report. Am J Psychiatry 1966; 123 (3): 351–2PubMed
25.
go back to reference Buckley C., Thomas V., Lewin J., et al. Stelazine-induced pigmentation. Clin Exp Dermatol 1994; 19 (2): 149–51PubMedCrossRef Buckley C., Thomas V., Lewin J., et al. Stelazine-induced pigmentation. Clin Exp Dermatol 1994; 19 (2): 149–51PubMedCrossRef
26.
go back to reference Lal S., Bloom D., Silver B., et al. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci 1993; 18 (4): 173–7PubMed Lal S., Bloom D., Silver B., et al. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes. J Psychiatry Neurosci 1993; 18 (4): 173–7PubMed
27.
go back to reference Bloom D., Krishnan B., Thavundayil J.X., et al. Resolution of chlorpromazineinduced cutaneous pigmentation following substitution with levomepromazine or other neuroleptics. Acta Psychiatr Scand 1993; 87 (3): 223–4PubMedCrossRef Bloom D., Krishnan B., Thavundayil J.X., et al. Resolution of chlorpromazineinduced cutaneous pigmentation following substitution with levomepromazine or other neuroleptics. Acta Psychiatr Scand 1993; 87 (3): 223–4PubMedCrossRef
28.
go back to reference Thompson T.R., Lal S., Yassa R., et al. Resolution of chlorpromazine-induced pigmentation with haloperidol substitution. Acta Psychiatr Scand 1988; 78 (6): 763–5PubMedCrossRef Thompson T.R., Lal S., Yassa R., et al. Resolution of chlorpromazine-induced pigmentation with haloperidol substitution. Acta Psychiatr Scand 1988; 78 (6): 763–5PubMedCrossRef
29.
go back to reference Ewing D.G., Einarson T.R. Loxapine as an alternative to phenothiazines in a case of oculocutaneous skin pigmentation. Am J Psychiatry 1981; 138 (12): 1631–2PubMed Ewing D.G., Einarson T.R. Loxapine as an alternative to phenothiazines in a case of oculocutaneous skin pigmentation. Am J Psychiatry 1981; 138 (12): 1631–2PubMed
30.
go back to reference Lal S., Lal S. Chlorpromazine-induced cutaneous pigmentation: effect of replacement with clozapine [letter]. J Psychiatry Neurosci 2000; 25 (3): 281PubMed Lal S., Lal S. Chlorpromazine-induced cutaneous pigmentation: effect of replacement with clozapine [letter]. J Psychiatry Neurosci 2000; 25 (3): 281PubMed
31.
go back to reference Lautenschlager S., Itin P.H. Reticulate, patchy and mottled pigmentation of the neck: acquired forms. Dermatology 1998; 197 (3): 291–6PubMedCrossRef Lautenschlager S., Itin P.H. Reticulate, patchy and mottled pigmentation of the neck: acquired forms. Dermatology 1998; 197 (3): 291–6PubMedCrossRef
32.
go back to reference Benning T.L., McCormack K.M., Ingram P., et al. Microprobe analysis of chlorpromazine pigmentation. Arch Dermatol 1988; 124 (10): 1541–4PubMedCrossRef Benning T.L., McCormack K.M., Ingram P., et al. Microprobe analysis of chlorpromazine pigmentation. Arch Dermatol 1988; 124 (10): 1541–4PubMedCrossRef
33.
go back to reference Rohrborn W., Brauninger W. Thioridazine photoallergy [letter]. Contact Dermatitis 1987; 17 (4): 241PubMedCrossRef Rohrborn W., Brauninger W. Thioridazine photoallergy [letter]. Contact Dermatitis 1987; 17 (4): 241PubMedCrossRef
35.
go back to reference Satanove A., McIntosh J.S. Phototoxic reactions induced by high doses of chlorpromazine and thioridazine. JAMA 1967; 200 (3): 209–12PubMedCrossRef Satanove A., McIntosh J.S. Phototoxic reactions induced by high doses of chlorpromazine and thioridazine. JAMA 1967; 200 (3): 209–12PubMedCrossRef
36.
go back to reference Torinuki W. Contact dermatitis to biperiden and photocontact dermatitis to phenothiazines in a pharmacist. Tohoku J Exp Med 1995; 176 (4): 249–52PubMedCrossRef Torinuki W. Contact dermatitis to biperiden and photocontact dermatitis to phenothiazines in a pharmacist. Tohoku J Exp Med 1995; 176 (4): 249–52PubMedCrossRef
37.
go back to reference Harth Y., Rapport M. Phototoxicity associated with antipsychotics, antidepressants, and anxiolytics. Drug Saf 1996; 14: 252–9PubMedCrossRef Harth Y., Rapport M. Phototoxicity associated with antipsychotics, antidepressants, and anxiolytics. Drug Saf 1996; 14: 252–9PubMedCrossRef
39.
go back to reference Ban T.A., Guy W., Wilson W.H. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Can J Psychiatry 1985; 30 (6): 406–8PubMed Ban T.A., Guy W., Wilson W.H. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Can J Psychiatry 1985; 30 (6): 406–8PubMed
40.
go back to reference Satanove A. Pigmentation due to phenothiazines in high and prolonged dosage. JAMA 1965; 191: 263–8PubMedCrossRef Satanove A. Pigmentation due to phenothiazines in high and prolonged dosage. JAMA 1965; 191: 263–8PubMedCrossRef
42.
go back to reference Greiner A.C., Berry K. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can Med Assoc J 1964; 90: 663–4PubMed Greiner A.C., Berry K. Skin pigmentation and corneal and lens opacities with prolonged chlorpromazine therapy. Can Med Assoc J 1964; 90: 663–4PubMed
43.
go back to reference Chignell C.F., Motten A.G., Buettner G.R. Photoinduced free radicals from chlorpromazine and related phenothiazines: relationship to phenothiazine-induced photosensitization. Environ Health Perspect 1985; 64: 103–10PubMedCrossRef Chignell C.F., Motten A.G., Buettner G.R. Photoinduced free radicals from chlorpromazine and related phenothiazines: relationship to phenothiazine-induced photosensitization. Environ Health Perspect 1985; 64: 103–10PubMedCrossRef
44.
go back to reference King D.L. Neuroleptics and the treatment of schizophrenia. In: King D.L., editor, for the Royal College of Psychiatrists. Seminars in clinical psychopharmacology. London: Gaskell, 1995 King D.L. Neuroleptics and the treatment of schizophrenia. In: King D.L., editor, for the Royal College of Psychiatrists. Seminars in clinical psychopharmacology. London: Gaskell, 1995
45.
go back to reference Ban T.A., Guy W., Wilson WH. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Can J Psychiatry 1985; 30: 406–8PubMed Ban T.A., Guy W., Wilson WH. Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients. Can J Psychiatry 1985; 30: 406–8PubMed
46.
go back to reference Bond W.S., Yee G.C. Occular and cutaneous effects of chronic phenothiazine therapy. Am J Hosp Pharm 1980; 37: 74–8PubMed Bond W.S., Yee G.C. Occular and cutaneous effects of chronic phenothiazine therapy. Am J Hosp Pharm 1980; 37: 74–8PubMed
47.
go back to reference Wolf M.E., Richer S., Berk M.A., et al. Cutaneous and ocular changes associated with the use of chlorpromazine. Int J Clin Pharmacol Ther Toxicol 1993; 31: 365–7PubMed Wolf M.E., Richer S., Berk M.A., et al. Cutaneous and ocular changes associated with the use of chlorpromazine. Int J Clin Pharmacol Ther Toxicol 1993; 31: 365–7PubMed
48.
go back to reference Kimyai-Asadi A., Harris J.C., Nousari H.C. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999; 60 (10): 714–25PubMedCrossRef Kimyai-Asadi A., Harris J.C., Nousari H.C. Critical overview: adverse cutaneous reactions to psychotropic medications. J Clin Psychiatry 1999; 60 (10): 714–25PubMedCrossRef
49.
go back to reference Thompson T.R., Lai S., Yassa R., et al. Resolution of chlorpromazine-induced pigmentation with haloperidol substitution. Acta Psychiatr Scand 1988; 78: 763–5PubMedCrossRef Thompson T.R., Lai S., Yassa R., et al. Resolution of chlorpromazine-induced pigmentation with haloperidol substitution. Acta Psychiatr Scand 1988; 78: 763–5PubMedCrossRef
50.
go back to reference Mercke Y., Sheng H., Khan T., et al. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000; 12 (1): 35–42PubMed Mercke Y., Sheng H., Khan T., et al. Hair loss in psychopharmacology. Ann Clin Psychiatry 2000; 12 (1): 35–42PubMed
51.
go back to reference Kubota T., Ishikura T., Jibiki I. Alopecia areata associated with haloperidol. Jpn J Psychiatry Neurol 1994; 48: 579–81PubMed Kubota T., Ishikura T., Jibiki I. Alopecia areata associated with haloperidol. Jpn J Psychiatry Neurol 1994; 48: 579–81PubMed
52.
go back to reference Warnock J.K. Psychotropic medication and drug-related alopecia. Psychosomatics 1991; 32 (2): 149–52PubMedCrossRef Warnock J.K. Psychotropic medication and drug-related alopecia. Psychosomatics 1991; 32 (2): 149–52PubMedCrossRef
54.
go back to reference Simpson G.H., Pi E.H., Sramek J.J. Neuroleptics and anti-psychotics. In: Dukes M.N.G., editor. Meyer’s side effects of drugs. Amsterdam: Elsevier, 1982: 95–108 Simpson G.H., Pi E.H., Sramek J.J. Neuroleptics and anti-psychotics. In: Dukes M.N.G., editor. Meyer’s side effects of drugs. Amsterdam: Elsevier, 1982: 95–108
55.
go back to reference Raz A., Bergman R., Eilam O., et al. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001; 321 (2): 156–8PubMedCrossRef Raz A., Bergman R., Eilam O., et al. A case report of olanzapine-induced hypersensitivity syndrome. Am J Med Sci 2001; 321 (2): 156–8PubMedCrossRef
56.
go back to reference Flint A. The skin in Parkinson’s disease. Prim Care 1977; 4: 475–80PubMed Flint A. The skin in Parkinson’s disease. Prim Care 1977; 4: 475–80PubMed
57.
go back to reference Binder R.I., Jonelis F.J. Seborrheic dermatitis: a newly reported side effect of neuroleptics. J Clin Psychiatry 1984; 45: 125–6PubMed Binder R.I., Jonelis F.J. Seborrheic dermatitis: a newly reported side effect of neuroleptics. J Clin Psychiatry 1984; 45: 125–6PubMed
58.
go back to reference Binder R.I., Jonelis F.J. Seborrheic dermatitis in neuroleptic-induced parkinsonism. Arch Dermatol 1983; 119: 473–5PubMedCrossRef Binder R.I., Jonelis F.J. Seborrheic dermatitis in neuroleptic-induced parkinsonism. Arch Dermatol 1983; 119: 473–5PubMedCrossRef
59.
go back to reference Daoud M.S., Schanbacher C.F., Dicken C.H. Recognizing cutaneous drug eruptions: reaction patterns provide clues to causes. Postgrad Med 1998; 104: 101–15PubMedCrossRef Daoud M.S., Schanbacher C.F., Dicken C.H. Recognizing cutaneous drug eruptions: reaction patterns provide clues to causes. Postgrad Med 1998; 104: 101–15PubMedCrossRef
Metadata
Title
Adverse Cutaneous Reactions to Antipsychotics
Authors
Dr Julia K. Warnock
David W. Morris
Publication date
01-12-2002
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 9/2002
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200203090-00005

Other articles of this Issue 9/2002

American Journal of Clinical Dermatology 9/2002 Go to the issue

Leading Article

Tumor Vaccines